125 filings
6-K
ARGX
Argen X SE
16 Apr 24
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
6:05am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:14am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:07am
6-K
ARGX
Argen X SE
26 Mar 24
Regulatory decision in Japan represents first global approval for VYVGART in ITP
6:05am
6-K
ARGX
Argen X SE
21 Mar 24
Current report (foreign)
6:07am
6-K
50gz0e5l0wn13
8 Mar 24
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years
6:05am
6-K
qy8k0w884n
29 Feb 24
Current report (foreign)
4:04pm
6-K
4lq2jy
20 Feb 24
If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP
6:06am
6-K
d43mgzkeq6sjny4w0hxm
18 Jan 24
Current report (foreign)
6:10am
6-K
ylmrffv1irgm
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
6-K
9fi3reod73zaxofxjlx
20 Dec 23
Current report (foreign)
6:00am
6-K
ad2t jz1rdqb1z
28 Nov 23
Current report (foreign)
6:01am
6-K
36juiign x2lf
17 Nov 23
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe
6:01am
6-K
6xolfjf98 8hv48zdt
1 Nov 23
Patients treated with VYVGART experienced consistent improvements on key quality of life measures based on long-term gMG extension data
4:01pm
6-K
wlwksn2ob 4l
31 Oct 23
Current report (foreign)
9:14am
6-K
dthegt4gmfoh5csz
21 Sep 23
Current report (foreign)
8:38am
6-K
qntonjlsgl17v 2pg
27 Jul 23
Current report (foreign)
6:02am
6-K
io8nr05avdam7zmjb4
20 Jul 23
Current report (foreign)
5:44pm
6-K
ab5imi1dn2916mby fr
17 Jul 23
Current report (foreign)
7:56am
6-K
uooqgs3
30 Jun 23
Current report (foreign)
4:02pm